Role of FABP3 as biomarker in Alzheimer's disease and synucleinopathies

Lipids are fundamental components of brain cells as they are involved in several essential processes like remodeling of plasma membrane, synaptic function and receptor–ligand interactions. Systemic and brain alterations in lipid metabolism have been linked to the pathogenesis of neurodegenerative disorders like dementia and parkinsonisms. Intracellular transport of lipids is regulated by fatty acid-binding proteins. Recently, a member of this family, the fatty acid-binding protein 3 has been proposed as a potential biomarker across a range of neurodegenerative diseases, including Alzheimer's disease and dementia with Lewy bodies. In this special report, we describe recent progresses in characterizing the role of fatty acid-binding protein 3 in neurodegeneration and its putative role as biomarker measurable in biological fluids.

• Publication year

  2018

• Venue

  Future Neurology

• Publication date

  2018-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/FNL-2018-0003
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Pathological role of lipid interaction with α-synuclein in Parkinson's disease.

  2018cited by this paper
• Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions

  2018cited by this paper
• Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry

  2017cited by this paper
• Diagnostic utility of cerebrospinal fluid α‐synuclein in Parkinson's disease: A systematic review and meta‐analysis

  2017cited by this paper
• [FTS3–02–01]: 2017 NIA‐AA RESEARCH FRAMEWORK TO INVESTIGATE THE ALZHEIMER's DISEASE CONTINUUM

  2017cited by this paper
• Framework : Towards a Biological Definition of Alzheimer ’ s Disease 1 2 draft 9-19-17 3 4 5

  2017cited by this paper
• Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia

  2017cited by this paper
• Dietary arachidonic acid as a risk factor for age-associated neurodegenerative diseases: Potential mechanisms.

  2016cited by this paper
• Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease.

  2015cited by this paper
• Late-onset dementia: a mosaic of prototypical pathologies modifiable by diet and lifestyle

  2015cited by this paper
• Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years

  2015cited by this paper
• Ptau-Aβ42 ratio as a continuous trait for biomarker discovery for early stage Alzheimer’s disease in multiplex immunoassay panels of Cerebrospinal fluid

  2014cited by this paper
• Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

  2014cited by this paper
• Phosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid.

  2014cited by this paper
• Long-chain polyunsaturated fatty acids (LCPUFA) from genesis to senescence: the influence of LCPUFA on neural development, aging, and neurodegeneration.

  2014cited by this paper
• Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration

  2014cited by this paper
• FABP3 Protein Promotes α-Synuclein Oligomerization Associated with 1-Methyl-1,2,3,6-tetrahydropiridine-induced Neurotoxicity*

  2014cited by this paper
• The Impact of Cholesterol, DHA, and Sphingolipids on Alzheimer's Disease

  2013cited by this paper
• Heart fatty acid binding protein and Aβ-associated Alzheimer’s neurodegeneration

  2013cited by this paper
• Fluid Biomarkers for Alzheimer’s Disease

  2013cited by this paper
• Are dopamine D2 receptors out of control in psychosis?

  2013cited by this paper
• Cross-talk of membrane lipids and Alzheimer-related proteins

  2013cited by this paper
• Cerebrospinal fluid biomarkers in Parkinson disease

  2013cited by this paper
• Dyslipidemia and the Risk of Alzheimer’s Disease

  2013cited by this paper
• Fluid biomarkers in Alzheimer’s disease – current concepts

  2013cited by this paper
• An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease

  2012cited by this paper
• Lipidomics of Alzheimer's disease: current status

  2012cited by this paper
• Brain imaging in Alzheimer disease.

  2012cited by this paper
• The multiple roles of fatty acid handling proteins in brain

  2012cited by this paper
• Cerebrospinal Fluid Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Combination with Subcortical and Cortical Biomarkers in Vascular Dementia and Alzheimer's Disease

  2011cited by this paper
• Modeling of Pathological Traits in Alzheimer's Disease Based on Systemic Extracellular Signaling Proteome*

  2011cited by this paper
• Brain‐specific fatty acid‐binding protein is elevated in serum of patients with dementia‐related diseases

  2011cited by this paper
• CSF Levels of Heart Fatty Acid Binding Protein are Altered During Early Phases of Alzheimer's Disease

  2011cited by this paper
• Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI

  2011cited by this paper
• In vivo demonstration that α-synuclein oligomers are toxic

  2011cited by this paper
• AGING NEUROSCIENCE Original Research Article

  2010cited by this paper
• Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies.

  2010cited by this paper
• Revising the definition of Alzheimer's disease: a new lexicon.

  2010cited by this paper
• Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease.

  2010cited by this paper
• Fatty acid binding proteins in brain development and disease.

  2010cited by this paper
• Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people.

  2010cited by this paper
• Novel CSF biomarkers for Alzheimer’s disease and mild cognitive impairment

  2010cited by this paper
• Polyunsaturated fatty acid-cholesterol interactions: domain formation in membranes.

  2009cited by this paper
• Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.

  2009cited by this paper
• Fatty acid binding protein: localization and functional significance in the brain.

  2008cited by this paper
• The emerging functions and mechanisms of mammalian fatty acid-binding proteins.

  2008cited by this paper
• Serum heart-fatty acid binding protein levels in patients with Lewy body disease.

  2008cited by this paper
• Nuanced roles of cytokines in three major human brain disorders.

  2008cited by this paper
• Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.

  2007cited by this paper
• Serum Heart-Type Fatty Acid-Binding Protein and Cerebrospinal Fluid Tau: Marker Candidates for Dementia with Lewy Bodies

  2007cited by this paper
• CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment

  2007cited by this paper
• Systemic infections and inflammation affect chronic neurodegeneration

  2007cited by this paper
• Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

  2007cited by this paper
• Fatty acid incorporation is decreased in astrocytes cultured from α‐synuclein gene‐ablated mice

  2005cited by this paper
• Brain arachidonic acid incorporation is decreased in heart fatty acid binding protein gene-ablated mice.

  2005cited by this paper
• Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction.

  2003cited by this paper
• The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease.

  2003cited by this paper
• Differential subcellular localization of two dopamine D2 receptor isoforms in transfected NG108‐15 cells

  2003cited by this paper
• Altered Fatty Acid Composition of Dopaminergic Neurons Expressing α-Synuclein and Human Brains with α-Synucleinopathies*

  2003cited by this paper
• Mechanisms of accumulation of arachidonate in phosphatidylinositol in yellowtail. A comparative study of acylation systems of phospholipids in rat and the fish species Seriola quinqueradiata.

  2003cited by this paper
• New insights into the structure and function of fatty acid-binding proteins

  2002cited by this paper
• α-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins

  2001cited by this paper
• Modification of dopamine neurotransmission in the nucleus accumbens of rats deficient in n-3 polyunsaturated fatty acids.

  2000cited by this paper
• The fatty acid transport function of fatty acid-binding proteins.

  2000cited by this paper
• Chronic administration of docosahexaenoic acid improves reference memory-related learning ability in young rats.

  1999cited by this paper
• α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies

  1998cited by this paper
• Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease

  1998cited by this paper
• Cytoplasmic fatty acid-binding proteins: their structure and genes.

  1995cited by this paper
• Fatty acid composition of brain phospholipids in aging and in Alzheimer’s disease

  1991cited by this paper
• Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal

  1988cited by this paper
• Partial purification of molecular weight 12 000 fatty acid binding proteins from rat brain and their effect on synaptosomal Na+-dependent amino acid uptake.

  1984cited by this paper

• V-set and immunoglobulin domain containing 4 as a potential predictor of Alzheimer's disease and advanced aging

  2025cites this paper
• Applying machine learning to high-dimensional proteomics datasets for the identification of Alzheimer’s disease biomarkers

  2025cites this paper
• The Role of Fatty Acid Binding Proteins in Neuropsychiatric Diseases: A Narrative Review.

  2025cites this paper
• Biological effects of sodium phenylbutyrate and taurursodiol in Alzheimer's disease

  2024cites this paper
• Cerebrospinal fluid biomarker profiling of diverse pathophysiological domains in Alzheimer's disease

  2024cites this paper
• Fatty acid–binding proteins 3, 7, and 8 bind cholesterol and facilitate its egress from lysosomes

  2024cites this paper
• Fatty acid binding protein as a new age biomarker.

  2024cites this paper
• Exploring the Dynamic Changes of Brain Lipids, Lipid Rafts, and Lipid Droplets in Aging and Alzheimer’s Disease

  2024cites this paper
• Research Online

  2023cites this paper
• Fatty-Acid-Binding Proteins: From Lipid Transporters to Disease Biomarkers

  2023cites this paper
• Pathogenic Impact of Fatty Acid-Binding Proteins in Parkinson’s Disease—Potential Biomarkers and Therapeutic Targets

  2023cites this paper
• Lipid Mediated Brain Disorders: A Perspective.

  2023cites this paper
• Fatty Acid-Binding Proteins: Their Roles in Ischemic Stroke and Potential as Drug Targets

  2022cites this paper
• Scientific and Regulatory Policy Committee Points to Consider: Integration of Clinical Pathology Data With Anatomic Pathology Data in Nonclinical Toxicology Studies

  2022cites this paper
• Scientific and Regulatory Policy Committee Points to Consider: Integration of Clinical Pathology Data With Anatomic Pathology Data in Nonclinical Toxicology Studies.

  2022cites this paper
• Fatty Acid-Binding Protein 3 Is a Marker of Neurodegeneration and White Matter Hyperintensity Burden in Mexican American Older Adults

  2022influential citation
• Exploring the Role of Lipid-Binding Proteins and Oxidative Stress in Neurodegenerative Disorders: A Focus on the Neuroprotective Effects of Nutraceutical Supplementation and Physical Exercise

  2022cites this paper
• Cerebrospinal fluid levels of fatty acid–binding protein 3 are associated with likelihood of amyloidopathy in cognitively healthy individuals

  2022cites this paper
• Genetic Architecture and Molecular, Imaging and Prodromic Markers in Dementia with Lewy Bodies: State of the Art, Opportunities and Challenges

  2021cites this paper
• Fatty Acid-Binding Proteins Aggravate Cerebral Ischemia-Reperfusion Injury in Mice

  2021cites this paper
• The Other Side of Alzheimer’s Disease: Influence of Metabolic Disorder Features for Novel Diagnostic Biomarkers

  2020cites this paper
• Anti-Epileptic Effects of FABP3 Ligand MF1 through the Benzodiazepine Recognition Site of the GABAA Receptor

  2020cites this paper
• APOE4 Copy Number-Dependent Proteomic Changes in the Cerebrospinal Fluid

  2020cites this paper
• Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease

  2020cites this paper
• Triple-Knockout, Synuclein-Free Mice Display Compromised Lipid Pattern

  2020cites this paper
• Novel fluid biomarkers to differentiate frontotemporal dementia and dementia with Lewy bodies from Alzheimer's disease: A systematic review.

  2020cites this paper
• Plasma Lipidomic Analyses in Cohorts With mTBI and/or PTSD Reveal Lipids Differentially Associated With Diagnosis and APOE ε4 Carrier Status

  2020cites this paper
• New insights in the opening mechanism of the heart-type fatty acid binding protein in its apo form (apo-FABP3)

  2019cites this paper
• Parkinson's and Lewy body dementia CSF biomarkers.

  2019cites this paper
• Advances and considerations in AD tau-targeted immunotherapy

  2019cites this paper
• Welcome to the 14th Volume of Future Neurology

  2019cites this paper
• Lipid and Lipid Raft Alteration in Aging and Neurodegenerative Diseases: A Window for the Development of New Biomarkers

  2019cites this paper